Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CFI-402411 |
Trade Name | |
Synonyms | CFI 402411|CFI402411 |
Drug Descriptions |
CFI-402411 inhibits HPK1 (MAP4K1), potentially leading to enhanced T-lymphocyte activation and antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | MAP4K1 Inhibitor 7 |
CAS Registry Number | NA |
NCIT ID | C176963 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CFI-402411 | CFI-402411 | 0 | 1 |
CFI-402411 + Pembrolizumab | CFI-402411 Pembrolizumab | 0 | 1 |